Skip to main content
OpenTrials
Completed

NCT Number: NCT05158764

Efficacy and Safety of URGOBD001 Compression System

Evaluation of the efficacy (wound epithelialization and time to closure) and safety (emergence and nature of adverse event) of the new URGO BD001 compression system versus a reference compression in the local treatment of venous or mixed predominantly venous leg ulcers: prospective multicenter, randomized controlled, open-label clinical study

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Patricia SENET

Paris, 75000, France

About this study

This is a prospective, randomized, controlled, open-label, multicenter clinical trial conducted in patients with a leg ulcer of venous or mixed predominantly venous origin of stage C6 / C6r of the CEAP classification.

This study is carried out in around 55 French investigational centers. A total of 178 patients meeting the eligibility criteria will be included. The patients will be followed for 12 weeks and a total of 5 clinical evaluations will be carried out by the investigating centers.

A planimetric survey of the studied VLU is carried out during the initial assessment of the wound (Day 0) and at each assessment provided for in the protocol (Week 2, Week 4, Week 8 and Week 12).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient (≥ 18 years old), having given free, informed and written consent
  • Patient affiliated to a social security scheme
  • Patient agreeing to wear the study compression system daily
  • Patient with an ankle circumference between 18 and 25 cm
  • Target wound: stage C6 / C6r leg ulcer of the CEAP classification with a 0.8≤ ABPI≤1.3
  • Target wound with an area between 1 and 20 cm2
  • Target wound with age of ≤24 months

Criteria exclusion:

  • Patient with a systemic infection not controlled by appropriate antibiotic therapy
  • Patient having presented in the 3 months preceding his inclusion, a deep vein thrombosis
  • Patient with advanced stage II or stage III lymphoedema
  • Patient bedridden or spending less than an hour per day standing
  • Clinically infected target wound
  • Cancerized target wound

Treatment and study plan

Venous compression system of the lower limbs stage C6 / C6r of the CEAP classification

Device

Etiological treatment of venous disease of the lower limbs stage C6 / C6r

Other names: Etiological treatment of venous disease of the lower limbs stage C6 / C6r

Primary outcomes

  1. Complete closure of the Venous Leg Ulcer (VLU)

    Time frame: 12-week treament period

    Complete closure of the leg ulcer is defined by 100% re-epithelialization of the Venous Leg Ulcer (VLU)

Secondary outcomes

  1. Time to complete closure of the Venous Leg Ulcer (VLU)

    Time frame: 12-week treament period

    Time to complete closure of the Venous Leg Ulcer (VLU) is defined as the time from inclusion to the date of complete closure

  2. Safety analysis

    Time frame: 12-week treament period

    Nature and number of adverse event related to the use of the studied compression system (serious/ non-serious)

Sponsors and collaborators

Lead sponsor

Laboratoires URGO

Industry

Registry information

Official study title

Evaluation of the Efficacy and Safety of the New URGO BD001 Compression System Versus a Reference Compression in the Local Treatment of Venous or Mixed Predominantly Venous Leg Ulcers: a Prospective Open-label RCT

Acronym: FUTURE

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Dec 15, 2021
Registry last updated
Oct 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.